Pharmac is seeking feedback to fund two lung cancer drugs, which could treat over 400 patients in their first year of being accessible.
The drug-buying agency has reached provisional agreements with Keytruda and Tecentriq following budget increases in May.
Oncologists say the drugs can double survival rates for people with advanced cancer, and will particularly benefit Māori and Pasifika, who suffer disproportionately from the disease.
Pharmac's director of operations Lisa Williams spoke to Kim Hill.
